Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma

被引：0
|
作者：
Veenstra, David L. [1 ]
Guzauskas, Gregory F. [1 ]
Spencer, Scott J. [1 ]
Felizzi, Federico [2 ]
Launonen, Aino [2 ]
Dawson, Keith [3 ]
Masaquel, Anthony [3 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
biosimilars; cost-effectiveness; immunochemotherapy; IBCL; indolent B-cell lymphoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-199
引用
收藏
页码：S280 / S280
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients
    Ohno, Shinya
    Shoji, Ayako
    Hatake, Kiyohiko
    Oya, Naoko
    Igarashi, Ataru
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1130 - 1141
  • [2] Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Thuresson, Per-Olof
    Dawson, Keith
    Veenstra, David L.
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1668 - 1676
  • [3] Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view
    Thielen, Frederick W.
    Kersten, Marie-Jose
    Kuizenga, Pim
    Hoogendoorn, Mels
    Posthuma, Eduardus F. M.
    Stevens, Wendy B. C.
    Uyl-de Groot, Carin A.
    Blommestein, Hedwig M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1411 - 1422
  • [4] Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
    Ma, Jun
    Zhao, Donglu
    Zhen, Bihong
    Xia, Yan
    Gong, Qianyi
    Chen, Wendong
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (12)
  • [5] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [6] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
    Lang, Wenwang
    He, Yulong
    Hou, Changchun
    Li, Hua
    Jiang, Qinling
    Mei, Liuyong
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [7] Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Reyes, Carolina
    Bernaards, Coen
    Krivasi, Tania
    Veenstra, David L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) : 960 - 967
  • [8] Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada
    Zou, Denise
    Lee, Joseph
    Kansal, Anuraag
    Ma, Wenkang
    Harris, Mack
    Lisano, Julie
    Fenton, Keenan
    Yu, Kristina S.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 324 - 333
  • [9] Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
    Morschhauser, F.
    Fowler, N. H.
    Feugier, P.
    Bouabdallah, R.
    Tilly, H.
    Palomba, M. L.
    Fruchart, C.
    Libby, E. N.
    Casasnovas, R-O.
    Flinn, I. W.
    Haioun, C.
    Maisonneuve, H.
    Ysebaert, L.
    Bartlett, N. L.
    Bouabdallah, K.
    Brice, P.
    Ribrag, V.
    Daguindau, N.
    Le Gouill, S.
    Pica, G. M.
    Martin Garcia-Sancho, A.
    Lopez-Guillermo, A.
    Larouche, J-F.
    Ando, K.
    Gomes da Silva, M.
    Andre, M.
    Zachee, P.
    Sehn, L. H.
    Tobinai, K.
    Cartron, G.
    Liu, D.
    Wang, J.
    Xerri, L.
    Salles, G. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10): : 934 - 947
  • [10] Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China
    Lin, Nanlong
    Chen, Shiting
    Zheng, Zhiwei
    Song, Xiaobing
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 205 - 213
12345